Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma

Venkata K. Pokuri, Johar R. Syed, Zhengyu Yang, Erinn P. Field, Susanna Cyriac, Roberto Pili, Ellis Glenn Levine, Gissou Azabdaftari, Donald L. Trump, Khurshid Guru, Saby George

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background Randomized trials have supported the use of cisplatin-based neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC) owing to the survival advantage, which has correlated with downstaging of the cancer to pT0. Only 30% to 40% of patients receiving NAC have attained a pT0 response at cystectomy; the remaining have either residual disease or progression. We aimed to identify the factors that could predict a pT0 response to NAC. Patients and Methods Of 336 patients who had undergone robotic cystectomy at our institute from May 2007 to March 2014, we identified 50 patients who had undergone NAC for MIBC. We conducted a retrospective study, dividing these 50 patients into 2 groups, those with and without a pT0. Factors, including age, histologic features, hydronephrosis at initial presentation, and chemotherapy type, were examined by both univariate and multivariate logistic regression analysis. Results Of the 50 patients, 14 (28%) had pT0 at cystectomy, 20 (40%) had progressive disease, and 16 (32%) had residual disease. The median age was 67.5 years, the median glomerular filtration rate at presentation was 87.5 mL/min, the patients had undergone a median of 3 NAC cycles, and the median time from the end of chemotherapy to surgery was 4 weeks. The odds of a pT0 response for pure urothelial carcinoma (UC) were approximately 11 times greater relative to cancers with transitional cell variant histologic features or mixed tumors (odds ratio 0.09, 95% confidence interval 0.021-0.380; P =.0011), including squamous, glandular differentiation, small cell, micropapillary, sarcomatoid, nested component, lymphoepithelioma-like, and plasmacytoid variants. Conclusion The presence of pure UC favored a pT0 response to NAC compared with those with variant histologic features or mixed tumors. These potential predictors warrant prospective validation to allow the ideal selection of patients for NAC.

Original languageEnglish (US)
Pages (from-to)e59-e65
JournalClinical Genitourinary Cancer
Volume14
Issue number1
DOIs
StatePublished - Feb 1 2016

Fingerprint

Urinary Bladder
Carcinoma
Drug Therapy
Muscles
Cystectomy
Neoplasms
Hydronephrosis
Age Factors
Robotics
Glomerular Filtration Rate
Patient Selection
Cisplatin
Disease Progression
Cell Differentiation
Retrospective Studies
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals
Survival

Keywords

  • Complete pathological response
  • Mixed tumors
  • Muscle-invasive
  • Neo-adjuvant chemotherapy
  • Predictors
  • Urothelial carcinoma
  • Variant histology

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. / Pokuri, Venkata K.; Syed, Johar R.; Yang, Zhengyu; Field, Erinn P.; Cyriac, Susanna; Pili, Roberto; Levine, Ellis Glenn; Azabdaftari, Gissou; Trump, Donald L.; Guru, Khurshid; George, Saby.

In: Clinical Genitourinary Cancer, Vol. 14, No. 1, 01.02.2016, p. e59-e65.

Research output: Contribution to journalArticle

Pokuri, VK, Syed, JR, Yang, Z, Field, EP, Cyriac, S, Pili, R, Levine, EG, Azabdaftari, G, Trump, DL, Guru, K & George, S 2016, 'Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma', Clinical Genitourinary Cancer, vol. 14, no. 1, pp. e59-e65. https://doi.org/10.1016/j.clgc.2015.09.013
Pokuri, Venkata K. ; Syed, Johar R. ; Yang, Zhengyu ; Field, Erinn P. ; Cyriac, Susanna ; Pili, Roberto ; Levine, Ellis Glenn ; Azabdaftari, Gissou ; Trump, Donald L. ; Guru, Khurshid ; George, Saby. / Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. In: Clinical Genitourinary Cancer. 2016 ; Vol. 14, No. 1. pp. e59-e65.
@article{d065c779d54c4b74b1db200c0dce742b,
title = "Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma",
abstract = "Background Randomized trials have supported the use of cisplatin-based neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC) owing to the survival advantage, which has correlated with downstaging of the cancer to pT0. Only 30{\%} to 40{\%} of patients receiving NAC have attained a pT0 response at cystectomy; the remaining have either residual disease or progression. We aimed to identify the factors that could predict a pT0 response to NAC. Patients and Methods Of 336 patients who had undergone robotic cystectomy at our institute from May 2007 to March 2014, we identified 50 patients who had undergone NAC for MIBC. We conducted a retrospective study, dividing these 50 patients into 2 groups, those with and without a pT0. Factors, including age, histologic features, hydronephrosis at initial presentation, and chemotherapy type, were examined by both univariate and multivariate logistic regression analysis. Results Of the 50 patients, 14 (28{\%}) had pT0 at cystectomy, 20 (40{\%}) had progressive disease, and 16 (32{\%}) had residual disease. The median age was 67.5 years, the median glomerular filtration rate at presentation was 87.5 mL/min, the patients had undergone a median of 3 NAC cycles, and the median time from the end of chemotherapy to surgery was 4 weeks. The odds of a pT0 response for pure urothelial carcinoma (UC) were approximately 11 times greater relative to cancers with transitional cell variant histologic features or mixed tumors (odds ratio 0.09, 95{\%} confidence interval 0.021-0.380; P =.0011), including squamous, glandular differentiation, small cell, micropapillary, sarcomatoid, nested component, lymphoepithelioma-like, and plasmacytoid variants. Conclusion The presence of pure UC favored a pT0 response to NAC compared with those with variant histologic features or mixed tumors. These potential predictors warrant prospective validation to allow the ideal selection of patients for NAC.",
keywords = "Complete pathological response, Mixed tumors, Muscle-invasive, Neo-adjuvant chemotherapy, Predictors, Urothelial carcinoma, Variant histology",
author = "Pokuri, {Venkata K.} and Syed, {Johar R.} and Zhengyu Yang and Field, {Erinn P.} and Susanna Cyriac and Roberto Pili and Levine, {Ellis Glenn} and Gissou Azabdaftari and Trump, {Donald L.} and Khurshid Guru and Saby George",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.clgc.2015.09.013",
language = "English (US)",
volume = "14",
pages = "e59--e65",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma

AU - Pokuri, Venkata K.

AU - Syed, Johar R.

AU - Yang, Zhengyu

AU - Field, Erinn P.

AU - Cyriac, Susanna

AU - Pili, Roberto

AU - Levine, Ellis Glenn

AU - Azabdaftari, Gissou

AU - Trump, Donald L.

AU - Guru, Khurshid

AU - George, Saby

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background Randomized trials have supported the use of cisplatin-based neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC) owing to the survival advantage, which has correlated with downstaging of the cancer to pT0. Only 30% to 40% of patients receiving NAC have attained a pT0 response at cystectomy; the remaining have either residual disease or progression. We aimed to identify the factors that could predict a pT0 response to NAC. Patients and Methods Of 336 patients who had undergone robotic cystectomy at our institute from May 2007 to March 2014, we identified 50 patients who had undergone NAC for MIBC. We conducted a retrospective study, dividing these 50 patients into 2 groups, those with and without a pT0. Factors, including age, histologic features, hydronephrosis at initial presentation, and chemotherapy type, were examined by both univariate and multivariate logistic regression analysis. Results Of the 50 patients, 14 (28%) had pT0 at cystectomy, 20 (40%) had progressive disease, and 16 (32%) had residual disease. The median age was 67.5 years, the median glomerular filtration rate at presentation was 87.5 mL/min, the patients had undergone a median of 3 NAC cycles, and the median time from the end of chemotherapy to surgery was 4 weeks. The odds of a pT0 response for pure urothelial carcinoma (UC) were approximately 11 times greater relative to cancers with transitional cell variant histologic features or mixed tumors (odds ratio 0.09, 95% confidence interval 0.021-0.380; P =.0011), including squamous, glandular differentiation, small cell, micropapillary, sarcomatoid, nested component, lymphoepithelioma-like, and plasmacytoid variants. Conclusion The presence of pure UC favored a pT0 response to NAC compared with those with variant histologic features or mixed tumors. These potential predictors warrant prospective validation to allow the ideal selection of patients for NAC.

AB - Background Randomized trials have supported the use of cisplatin-based neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC) owing to the survival advantage, which has correlated with downstaging of the cancer to pT0. Only 30% to 40% of patients receiving NAC have attained a pT0 response at cystectomy; the remaining have either residual disease or progression. We aimed to identify the factors that could predict a pT0 response to NAC. Patients and Methods Of 336 patients who had undergone robotic cystectomy at our institute from May 2007 to March 2014, we identified 50 patients who had undergone NAC for MIBC. We conducted a retrospective study, dividing these 50 patients into 2 groups, those with and without a pT0. Factors, including age, histologic features, hydronephrosis at initial presentation, and chemotherapy type, were examined by both univariate and multivariate logistic regression analysis. Results Of the 50 patients, 14 (28%) had pT0 at cystectomy, 20 (40%) had progressive disease, and 16 (32%) had residual disease. The median age was 67.5 years, the median glomerular filtration rate at presentation was 87.5 mL/min, the patients had undergone a median of 3 NAC cycles, and the median time from the end of chemotherapy to surgery was 4 weeks. The odds of a pT0 response for pure urothelial carcinoma (UC) were approximately 11 times greater relative to cancers with transitional cell variant histologic features or mixed tumors (odds ratio 0.09, 95% confidence interval 0.021-0.380; P =.0011), including squamous, glandular differentiation, small cell, micropapillary, sarcomatoid, nested component, lymphoepithelioma-like, and plasmacytoid variants. Conclusion The presence of pure UC favored a pT0 response to NAC compared with those with variant histologic features or mixed tumors. These potential predictors warrant prospective validation to allow the ideal selection of patients for NAC.

KW - Complete pathological response

KW - Mixed tumors

KW - Muscle-invasive

KW - Neo-adjuvant chemotherapy

KW - Predictors

KW - Urothelial carcinoma

KW - Variant histology

UR - http://www.scopus.com/inward/record.url?scp=84952871261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952871261&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2015.09.013

DO - 10.1016/j.clgc.2015.09.013

M3 - Article

VL - 14

SP - e59-e65

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 1

ER -